Pipeline Insight: Anticonvulsants - Drug Versatility Crucial for Market Success

Introduction

The commercial potential of anticonvulsants market is beginning to be recognized, and the R&D pipeline is packed with numerous reformulations and innovative projects. Given the success of Pfizer’s market leading Neurontin, with sales of over $2bn in 2002 driven mainly by growth in the neuropathic pain market, companies are keen to expand the labeling of their products beyond epilepsy. 

Scope

Detailed coverage of the patient potential and unmet needs of key indications treated with anticonvulsants across the seven major markets 

Overview of drugs in Phase III, II, I and preclinical development, with profiles of key companies, namely Pfizer and UCB 

Profiles of existing compounds undergoing development for secondary indications, and insight into innovative early stage products 

Evaluation of key clinical trials in the treatment of epilepsy, neuropathic pain, migraine and bipolar disorders, with revenue forecasts to 2011 

Report Highlights

Anticonvulsants are used in a plethora of different disease areas, and in various ways. However, there are four areas in which these drugs are used which can be considered to be the most important, due to the higher prevalence rates of the disorders, and the level of use of the anticonvulsants. 

Datamonitor believes the most significant factor to affect Neurontin’s revenues is the entry of generic competition in the US, expected in late 2003. Pfizer has attempted to extend its protection until pregabalin, the follow-up compound, had been launched. However, delays to development mean pregabalin is not expected to be launched until 2004. 

Reasons to Purchase

Enhance your knowledge of the anticonvulsant market by understanding which indications offer the best commercial opportunities 

Understand the anticonvulsant market unmet needs to devise market-penetrating strategies 

Benchmark your company against the main players in the anticonvulsant market, and identify in-licensing and co-promotional opportunities 

Publisher: Datamonitor CNS Central Nervous System Reports 

To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_CNS.html#a100